Zydus Life Science and Guardant Health to Co-Market Guardant360 Genomic Test in India
Shots:
- Under the agreement both the companies will jointly co-promote the Guardant360 portfolio of liquid and tissue biopsy across India and Nepal
- Guardant360 & Guardant360 TissueNext tests are precision oncology next-gen sequencing test which provide comprehensive genomic profiling and the Guardant360 Response test can be used for monitoring response to treatment
- Guardant360 is a minimally invasive liquid biopsy test provides CGP of all solid tumours by analysing ctDNA. This genomic profiling also secured insurance coverage in the US in May’23
Ref: Zydus Life Science | Image: Zydus Life Science
Related News:- Guardant Health Receives MHLW Approval for Guardant360 CDx as Companion Diagnostic to Enhertu for Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
